Pipeline

New Paragraph

Pipeline

Interplay Bio is seeking to secure partnerships with pharmaceutical companies for further development and commercialization of its pipeline of TPD drug candidates

POWER OF THE PLATFORM


Utilizing our LigandPro platform, we screened ten (10) FDA approved small molecules to identify their poly-pharmacology. We identified 100+ protein interactions of interest and through literature mining identified thirty (30) of these to have useful disease targets including:

Cancers

Multiple types

Neurodegenerative Diseases

Such as Alzheimers, Parkinsons and Huntingtons disease

Metabolic Disorders

Such as Diabetes and Obesity

A diverse array of protein targets underscores the potential broad applicability of our findings across multiple therapeutic areas

The agents below are currently are available for Lead Optimization

  • IPB 106

    Protein X is a promising disease target for pancreatic ductal adenocarcinoma (PDAC) due to its frequent overexpression in tumor tissues, which correlates with poor prognosis and advanced disease. Protein X's role as an m6A reader protein and its involvement in regulating multiple cancer-related genes make it an attractive therapeutic target. Inhibition of Protein X has shown potential in suppressing PDAC growth, suggesting that targeting this protein could offer new treatment strategies for this aggressive cancer.

  • IPB 107

    Protein X is a promising disease target for pancreatic ductal adenocarcinoma (PDAC) due to its frequent overexpression in tumor tissues, which correlates with poor prognosis and advanced disease. Protein X's role as an m6A reader protein and its involvement in regulating multiple cancer-related genes make it an attractive therapeutic target. Inhibition of Protein X has shown potential in suppressing PDAC growth, suggesting that targeting this protein could offer new treatment strategies for this aggressive cancer.
Share by: